Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KDM6B | O15054 | 1/20 | 0.54 |
| ▸ | KDM4A | O75164 | 1/20 | 0.54 |
| ▸ | KDM5C | P41229 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.54 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.54 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | MARS1 | P56192 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117407 | 0.88 | KDM4C (0.59) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL3208897 | 0.83 | KDM4C (0.54) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL3205630 | 0.82 | TSHR (0.55) | KMOMAP4K4 | |
| SCHEMBL3200062 | 0.82 | TSHR (0.59) | KMO | |
| SCHEMBL29788328 | 0.82 | KDM4E (0.61) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL5858 | 0.82 | KDM4E (0.61) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL29306758 | 0.81 | NPC1 (0.46) | KDM4ETGFBR1CHEK2 | |
| Hydrochloric Acid SCHEMBL3066744 | 0.80 | KDM4E (0.59) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL28399239 | 0.80 | KDM4E (0.59) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL3208905 | 0.80 | KDM4C (0.50) | KDM4EKDM6BKDM4AKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | KDM4E 987/4885KDM6B 802/4885KDM4A 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.